KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBITDA Margin: 2016-2024

Historic EBITDA Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to 8.92%.

  • Amneal Pharmaceuticals' EBITDA Margin fell 368.00% to 8.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.19%, marking a year-over-year increase of 519.00%. This contributed to the annual value of 8.92% for FY2024, which is 39.00% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its EBITDA Margin stood at 8.92% for FY2024, which was up 4.51% from 8.54% recorded in FY2023.
  • Amneal Pharmaceuticals' EBITDA Margin's 5-year high stood at 8.92% during FY2024, with a 5-year trough of -4.29% in FY2022.
  • For the 3-year period, Amneal Pharmaceuticals' EBITDA Margin averaged around 4.39%, with its median value being 8.54% (2023).
  • In the last 5 years, Amneal Pharmaceuticals' EBITDA Margin soared by 1,987bps in 2020 and then slumped by 1,159bps in 2022.
  • Amneal Pharmaceuticals' EBITDA Margin (Yearly) stood at 4.57% in 2020, then soared by 272bps to 7.29% in 2021, then plummeted by 1,159bps to -4.29% in 2022, then soared by 1,283bps to 8.54% in 2023, then surged by 39bps to 8.92% in 2024.